Table 5.

Anti-inflammatory bioactive peptides.

Peptide	LC cell lines	Cytotoxicity (IC50)	Type/Structure	Highlights	References
Smp24	A549, H3122, PC-9, and H460: 4.06 to 7.07 μM	MRC-5: 14.68 μM	AMP	The peptide was able to kill A549 cells through the cell membrane, mitochondrial and nuclear destruction.	Nagaraj et al. (2022)
P-113 and its derivatives	H1975, A549 and PC 9 21.32 to >200 μM	NR	AMP	AMPs induce the death of immunogenic cells derived from cancer lines and release potent danger-associated molecular patterns.	Cheah et al. (2022)
NKTP-3	A427	NR	Cell-permeable Cyclic D-peptide	Dual-targeting (NRP1 and KRASG12D) peptide for therapy of LC.	Zhou et al. (2022)
BR2-2xPPD	A549, PC9-6 M, PC9-GR and PC9-ER (resistant cell lines): 2.5 μM	BEAS-2B and HaCaT: non-toxic	Cell-penetrating peptides (CPP)	CPPs induced cell cycle arrest by inhibiting the expression of cyclin D1 and CDK2 genes in A549 wild-type epidermal growth factor receptor cells.	Kaewjanthong et al. (2022)
P7	A549 and H1975, A549/CD133+ cells: 50 ηM.	NR	Peptide-drug conjugate	Docetaxel-P7 induced unfolded protein response and subsequent apoptosis by degrading Hsp90, while awakening and killing the dormant cancer stem cells.	Jiang Y. et al. (2022)
D-LAK-120A	A549, H358, H1975, and HCC827: 4 to 5.5 μM	Healthy lung cell line: 8.40 μM	AMP	D-LAK-120A inhibited cancer cell proliferation via both membranolytic and non-membranolytic pathways. AMP significantly inhibited colony formation and cancer metastasis in vitro.	Patil and Kunda (2022a)
EIP103	A549: 1 μM and H446: 10 μM.	DC2.4: non-toxic	Targeting peptide + CPP	Peptides that can specifically target nucleus receptor LC and improve the anti-tumor efficacy.	Jiang M. et al. (2022)
Mastoparan	A549: 1.3 μM	NR	Peptide-drug conjugate	Significantly higher cell counts were found in G2-M phase after treatment with mastoparan-alendronate sodium nanoconjugates.	Alhakamy et al. (2022)
ACPP-p21Ras scFv	A549, SW480, U251 and Huh7	BEAS-2B	CPP	Potential antitumor drug for Ras gene-driven LC	Du et al. (2022)
Peptide from circPPP1R12A-73aa protein	A549 and H1299	BEAS-2B	NR	NSCLC cell proliferation was promoted by circPPP1R12A-73aa translated from circPPP1R12A through the AKT pathway.	Zhao et al. (2022)
d-peptide VAP	A549-luc	NR	Conjugate peptides	The D peptide modification markedly enhanced the tumor-targeting efficiency of nanodisks, thereby improving the anti-tumor properties of non-small cell LC efficacy of the drug delivery system.	Song et al. (2022)
CIGB-552 peptide	NCI-H460, A549 and TC-1 (in vivo)	NR	Antitumoral peptide	The results demonstrated a clear synergic effect between 37.5 μM of CIGB-552 and 5 μM of cisplatin under a concomitant scheme, on proliferation inhibition, cell cycle arrest, apoptosis induction and oxidative stress response.	Gomez Rodriguez et al. (2022)
CP7	A549: 14.94 μg/mL	NR	Targeting peptide	In vivo experiments proved that siRNA/liposome-PEG-CP7 has excellent tumor targeting and tumor inhibition function in tumor-bearing mice.	Dong et al. (2022)
Nisin ZP	A549: 132.4 μM H1299: 137.3 μM	HEK293: > 300 μM	AMP	The cell cycle arrest suggested accumulation of cells in initial G0/G1 phase, which ultimately culminated in apoptotic cell death of NSCLC cells regardless of p53 tumor protein expression.	Patil and Kunda (2022b)
cRGD polypeptide	LL/2	NR	Conjugate peptides	It exhibited good tumor-targeting capability, good biodegradability and biocompatibility. Combined treatment displayed enhanced anti-tumor and anti-metastatic ability in LC therapy.	Zhang et al. (2022)
Laterosporulin10 (LS10)	MCF-7, HEK293T, HT1080, HeLa and H1299: <10 μM	Prostate epithelium cells (RWPE-1): >15 μM	AMP	Laterosporulin10 is an anticancer bacteriocin that, at low and high doses, induces the death of cancer cells by apoptosis and necrosis, respectively. In light of the study’s overall findings, AMP is an anticancer peptide that may be further developed for medicinal uses.	Baindara et al. (2017)